Chapter 17: Physical Treatments in Psychology

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we are tackling, I think, one of the most challenging and frankly one of the most important areas in all of psychology,

the use of physical treatments for mental illness.

Yeah, this is a huge one.

We're really going into the biological side of psychiatry here.

We're talking about how we physically intervene in the brain with chemicals, with electricity, even with surgery.

And our mission for this Deep Dive is, well, it's two -fold.

First we're going to unpack the major tools in the psychiatrist's kit.

So that's the tranquilizers, antidepressants, ECT, all of it.

But then, and this is the really crucial part, we have to look at the massive struggle behind it all.

How do we even know if these treatments actually work and why?

It's a huge question.

It really is.

And the history here is, well, it's long and it's not always pretty.

I mean, we're talking about attempts to physically alter the mind that go way back.

Way, way back.

To the Neolithic period, we have evidence of crude craniotomies, basically drilling holes in people's skulls.

Wow.

And the thinking there was… The best guess is that they were trying to, quote,

release evil spirits.

It was the most direct physical intervention they could imagine for profound mental distress.

And that image, it just perfectly sets the stage for the modern dilemma, doesn't it?

I mean, a psychiatrist today has choices that are obviously way more advanced and safer, but on a fundamental level.

The choices are similar.

Offer a potion, a drug.

Induce a state of temporary unconsciousness ECT.

Or in extreme cases, recommend cranial surgery.

The tools have changed, but the fundamental challenge hasn't.

You're still trying to figure out what's really working and why, especially when you have things like spontaneous recovery or just the power of belief messing with your results.

It's maybe the single -heartedest problem in all of clinical science.

Okay, so let's start right there.

Section one.

The challenge of assessing effectiveness.

When we're talking about something like depression or schizophrenia, why is it so incredibly hard to study scientifically?

Well, the first thing you run into is just the emotional atmosphere.

It's intense.

You have patients who are suffering terribly and they're desperate for relief.

And clinicians who desperately want to help them.

Exactly.

So hope, belief,

expectation.

These are running incredibly high on both sides.

And those subjective forces create these immensely powerful placebo effects that can really confound the science.

Right.

So a patient gets better after, say, starting a new drug.

How does anyone, the patient, the doctor, the researcher, know for sure what caused the improvement?

That's the core problem.

You're left trying to pick apart the contribution of three different factors that are all tangled up together.

We call them the three confounders of recovery.

Okay, let's walk through them one by one.

So number one is the trickiest.

Spontaneous cure or spontaneous remission.

A lot of mental illnesses are episodic.

They have ups and downs.

People can just get better on their own.

They can.

So if you treat someone for six months and they recover, how do you know they wouldn't have just recovered on their own in seven months without any treatment at all?

You don't.

Okay, so that's factor one.

What's the second?

Factor two is the physical therapy itself.

This is the thing you're actually trying to test.

The drug, the electricity, the surgery,

the specific biological effect.

And the third factor.

That's everything else.

The psychotherapy, the environment, the change in attitude.

It's the supportive relationship you build with your doctor.

It's being in a structured hospital environment.

It's just a powerful belief that you're getting cutting edge care.

And all three are happening at the same time.

Almost always.

Which makes isolating the true effect of just the physical therapy, a factor two, nearly impossible.

And we have some pretty stark historical examples of how badly this confusion can lead researchers astray.

We do.

And they're pretty sobering.

The sources point to things like hydrotherapy using, you know, extreme jets of water or ice baths and insulin coma therapy.

These were seen as legitimate, powerful biological treatments at the time.

Absolutely.

Clinicians were totally convinced they were seeing specific biological effects.

But in reality.

It was mostly the placebo and the environment.

It was inseparable from it.

I mean, these procedures were dramatic.

They were intense.

They generated so much hope and required so much interaction with the staff.

A lot of the improvement wasn't from the cold water or the insulin shock.

It was from the sheer psychological force of the whole experience.

So to try and get around this, modern science developed its gold standard.

The double -blind controlled trial.

How is that supposed to solve the problem?

Well, the idea with a double -blind trial is to separate factor two, the drugs effect, from factor three, the placebo and environmental effects.

So you have one group that gets the real treatment.

And the control group gets a mock therapy, like a sugar pill.

A placebo, right.

And the double -blind part is the key.

Meaning, neither the patients nor the doctors and nurses assessing them know who is getting what.

Exactly.

That's supposed to control for all the expectation and bias and enthusiasm on both sides.

In theory, it lets you isolate the true biological effect of the drug.

In theory.

But this is where the theory just crashes into the messy reality of psychiatric drugs.

It really does.

Because you immediately hit this huge obstacle,

side effects.

Most of these really potent physical treatments have very complex and very, very obvious physical side effects.

Give us an example.

How does a side effect break the blind?

Okay, so a patient starts a new drug in a trial.

A few days later, they get a really dry mouth, their vision gets a bit blurry, maybe they get a noticeable tremor in their hand, or they feel dizzy when they stand up.

They know.

They know they're not on the sugar pill.

They know immediately.

And just as important, the nurse taking their blood pressure knows.

The psychiatrist observing them sees the tremor.

The blind is broken.

So you're not really running a double blind study anymore.

You're back to a situation where psychological expectancy is in full play and contaminating the results.

It completely undermines the whole method.

And you know, researchers try to get around it.

They might try to give the placebo group a pill that also causes a dry mouth, for instance.

But you can't replicate that whole complex cluster of side effects.

It's often impossible.

Or more to the point, it's unethical.

You can't just give someone a dangerous substance to mimic the symptoms of another dangerous substance just for the sake of the experiment.

So for a lot of the major physical treatments we use, a truly perfect, unbreakable double blind trial is just not available.

That's the hard truth of it.

And the problem actually goes even deeper.

There's what's called the specificity barrier.

Okay, what's that?

It's the fact that these drugs often work in a way that is different in kind in a mentally ill person versus a healthy person.

You can't just give an antidepressant to a healthy person and expect them to feel euphoric.

Exactly.

They don't.

Antidepressants don't make healthy people feel high or euphoric.

They seem to specifically correct a pathological state that exists in a depressed person.

They aren't just general mood elevators.

Which makes it hard to know what a control effect should even look like in a healthy subject.

Right.

And then you have one final barrier, which is just the state of psychiatric diagnosis itself.

Diagnostic disagreement.

Yeah.

I mean, unlike, say, a broken bone, which is obvious on an x -ray, psychiatric diagnosis can be subjective.

What one highly trained doctor calls schizoaffective disorder, another in the same hospital might call psychotic depression.

And if your basic categories are a bit fluid, then comparing results from different trials becomes a nightmare.

A total nightmare.

Because you might be comparing apples and oranges.

We use these big umbrella terms like schizophrenia or depression, but they probably cover dozens of different underlying biological conditions.

So a drug might work brilliantly for one subtype, but if your study lumps them all together, the results just look mediocre or inconclusive.

That's the problem.

So, okay, it's a pretty daunting context.

We have these incredibly powerful tools, but we're trying to measure them with a system that's constantly fighting against the complexities of the human mind and brain disease.

It is.

But with that in mind, with those limitations clear, let's now turn to the specific interventions.

And let's start with the drugs designed to manage acute psychosis, the tranquilizers.

And the first and most important group here are the phenothiazines.

You might hear them called major tranquilizers or, more commonly today,

antipsychotics.

The parent compound is phenothiazine, and the big names are drugs like chlorpromazine,

trifluoprazine.

Right, but chlorpromazine is the one that really started it all.

And what's so striking about these drugs is where they came from.

It wasn't psychology labs.

It was a completely different field of medicine.

Completely different.

The phenothiazine chemical family was originally used to treat worm infestations.

Wait, really?

Worms?

Worms.

It was only in 1950 when chlorpromazine was synthesized and used to make general anesthetics work better that someone noticed its psychiatric potential.

Because it had this unique calming effect on patients before surgery.

A really profound calming effect.

And psychiatrists, especially in France, jumped on that.

They saw its potential for the most agitated, most psychotic patients.

And this led to what our source calls a deluge of enthusiastic, if poorly controlled, observations.

You can just feel the excitement and desperation in that phrase.

I mean, you have these hospital wards filled with severely distressed people.

And suddenly this chemical seems to offer some hope.

And that hope definitely colored the early research.

It was hard to tell what was the drug and what was just the massive shift in morale in the hospitals.

But eventually the evidence became overwhelming.

Something real and substantial was happening.

Let's talk about the pharmacology, chlorpromazine.

Where in the brain is it working?

It mainly concentrates in the stem of the brain.

A really primitive, crucial area that controls things like arousal.

It's also excreted very slowly, which means it has a long -lasting action.

And the effects aren't static, right?

They change over time.

Yes, this is key.

The initial effect is this striking sedation.

That's useful for a crisis.

But that part wears off after a few days.

The real therapeutic effects are the chronic, long -term ones.

And psychologically, what are those long -term effects?

The drug reduces how much a person responds to external stimulation.

It dampens down their gross motor activity.

But, and this is important, it does it without making them weak or uncoordinated.

It also seems to severely affect conditioned avoidance reactions.

Meaning they're less likely to react with fear or panic to things that used to trigger them.

Exactly.

So the sedation is just an initial effect.

The real benefit is how it helps control the positive symptoms of schizophrenia.

The hallucinations, the delusions, the disordered thoughts, the extreme excitement.

Controlled trials show it's way better than a placebo for that.

But this brings us right back to our measurement problem.

This is like the poster child for the failure of the double -blind trial.

It absolutely is.

I mean, think about the side effects we mentioned.

Dry mouth, blurred vision, low blood pressure that makes you faint.

And the big one.

Parkinson's -like effects.

Tremors, rigidity, a shuffling walk.

That's from the drug's action on the basal ganglia.

Any patient with that cluster of symptoms knows for sure what group they're in.

100 percent.

The side effects are so distinct that comparing it to an inert sugar pill is, from a purely scientific standpoint, pretty weak.

So even though we all know clinically that these drugs work, the evidence isn't as pure as a scientific curist would demand because the blind is so easily broken.

And this ambiguity has fueled a really long -running debate about the long -term outlook for schizophrenia.

A huge debate.

On one hand, since these drugs were introduced, the average hospital stay has plummeted.

Discharge rates are way up.

It looks like a massive medical victory.

But the flip side of that is that readmission rates have also gone up.

Which forces you to ask a tough question.

Are we actually curing the illness or are we just getting much better at managing the acute episodes?

Researchers like Bluhler suggested that maybe we were underestimating how many people might have recovered on their own anyway.

So in that view, the phenolthiazines are getting maybe undue credit.

They help in a crisis, but they might not be fundamentally changing the disease's long -term course.

That's a huge distinction.

It is.

But even with all that controversy, the scientific consensus is that they do have a specific antipsychotic action.

And we have a really compelling theory for how it works from a researcher named Bradley.

Okay, let's really dig into Bradley's theory because this gets at the specific mechanism.

So Bradley's research shows something fascinating.

He found that chlorpromazine does not reduce the nerve signals going from the brain stem's arousal centers up to the cortex.

So the internal brain chatter is still happening.

Right.

But what it does do is it profoundly diminishes the effect of peripheral stimulation stuff from the outside world in activating those arousal centers in the first place.

So the internal engine is running, but all the sensory input, the noise, the lights, the distractions, is hitting the system with less force.

It's like turning down the volume on the outside world.

That's a perfect way to put it.

It improves the signal to noise ratio.

And this fits so well with one of the leading hypotheses of schizophrenia.

Which is that the patient has a problem with sensory filtering.

They can't suppress irrelevant information, so everything comes in at full blast, creating chaos.

And by turning down the arousing effect of all that peripheral noise,

the drug allows the patient's cortex to function more coherently.

It reduces the fuel for the hallucinations and the excitement.

That's a really satisfying explanation.

It is.

Now, there's a closely related group of drugs.

The butyrophenones.

And the sources say they do pretty much the same thing psychologically as the phenothiazines.

So why bother developing a whole new class?

The motivation was all about solving that side effect problem we just talked about.

The butyrophenones were designed to have much less effect on the peripheral nervous system while keeping the central effects in the brain.

So less of the autonomic sweat effects.

Less dry mouth, less blurry vision, less fainting.

That was the goal.

To create a cleaner drug.

One that wouldn't break the blind quite so easily.

A superior therapeutic agent.

And did it work?

Well, the controlled trials showed no real therapeutic advantage over the phenothiazines.

They worked, but they weren't better.

Which is an interesting finding in itself.

It suggests maybe those side effects weren't entirely irrelevant to the overall effect, or at least that getting rid of them didn't automatically make the drug better.

It's a subtle but important point for researchers, for sure.

Okay, let's shift gears now to probably the most widely prescribed class of all.

The minor tranquilizers.

The benzodiazepines.

Yeah, these are the household names.

Chloroazepoxide is Librium.

Diazepam is Valium.

Their use for anxiety in the general population is just massive.

And their mechanism is completely different from the antipsychotics.

Fundamentally different.

The phenothiazines were about filtering stimuli and arousal.

The benzos are more about global depression of neural activity.

They hit the limbic system, the brain's emotional center, the brain's stem arousal systems, and even neurons in the spinal cord.

So depressing activity in the limbic system would logically make you feel less emotional, less anxious.

It does.

The result is a patient who is, as the source puts it, tranquilized, sedated, and a rather limp.

But they're not useful for severe mental illness, for psychosis.

No.

Trials show they're pretty ineffective for that.

Their real demonstrated value is in treating neurotic anxieties.

How do they stack up against the older anxiety drugs, like the barbiturates?

Were they actually better at relieving anxiety?

Not really, no.

Not convincingly superior in that regard.

But they had one massive advantage that changed everything.

Safety.

Their safety profile in an overdose.

This is absolutely critical.

Many patients with anxiety also struggle with suicidal thoughts.

Barbiturates are incredibly lethal if you take too many.

Benzodiazepines are much, much safer in a suicide attempt.

So that safety advantage is really what explains their dominance.

It's almost the entire story.

It was a clear win for patient safety.

Okay, so that covers the tranquilizers.

Now we can move to the other side of the mood spectrum and look at treatments for depression.

And this brings up a really important question, right?

If we're looking at the big picture, how on earth did we stumble onto these treatments?

And what do they teach us about the chemistry of the brain?

Because, like the tranquilizers, these were also discovered by accident.

Total accidents.

They basically created one of the most important theories in psychiatry.

The monoimmune hypothesis.

By pure chance.

Let's start with the first class, the tricyclics.

Okay, so the very first one.

Imipramine was found in the late 1950s.

A Swiss doctor named Kuhn was actually looking for a new antipsychotic.

Something like chlorpromazine.

And imipramine was a total failure for schizophrenia.

A complete dud.

But Kuhn noticed that it seemed to have this specific delayed benefit for his patients with depression.

And the other class, the MAO inhibitors, came out of research on tuberculosis.

That's right.

The drug was called oproniazid.

It was an antibacterial.

But doctors noticed a very strange side effect in their TB patients.

They were becoming euphoric, intensely happy, even though they had this awful physical illness.

A clear signal that it had powerful mood -altering properties.

So what's the connection between these two totally different drug classes?

The connection is that they both mess with the brain's monoamine neurotransmitters.

Chemicals like serotonin and noradrenaline.

They both ultimately increase how much of these chemicals are available in the brain.

But they do it in different ways.

How do the tricyclics work?

The tricyclics, named for their three -ring chemical structure, work by blocking the reuptake of monoamines.

So after a neuron releases serotonin, for example, there's usually a little vacuum pump that sucks it back up to be reused.

Tricyclics block that pump.

So more of the chemical is left floating around in the synapse to stimulate the next neuron.

Precisely.

And the MAO inhibitors.

They inhibit an enzyme, monoamine oxidase.

Right.

And that enzyme's job is to break down monoamines inside the neuron.

So if you inhibit the enzyme, you get a bigger internal store of these chemicals, which leads to more being released.

Two different paths to the same result.

More monoamines.

But here's the big puzzle.

The clinical relief, the patient actually feeling better, takes anywhere from four days to three weeks to kick in.

And that delay is so important.

The chemical action blocking reuptake, or inhibiting the enzyme, that happens within hours.

But the therapeutic effect is weeks away.

Which tells you it's not a simple cause and effect.

It can't be.

The leading theory now is that the immediate drug action is just the first domino.

It kicks off a whole cascade of slower adaptive changes in the brain, maybe in the sensitivity of receptors or even the structure of neurons.

But the exact link is still a bit of a mystery.

So let's look at the data.

Table 17 .1 in our source material summarizes the double blind trials.

What does it tell us about how well these drugs work compared to placebo?

It tells us that Imipramen, the classic tricyclic, is very effective.

You've got 19 studies showing it was more effective than placebo, versus only six where it was equal or worse.

That's a really strong three to one signal.

And other tricyclics, like amitriptyline, show a similar pattern.

They do.

And you can contrast that with something like amphetamine, a stimulant.

It had zero studies showing it was better than placebo.

So this isn't just about stimulation.

It's a specific antidepressant effect.

It's interesting that even chlorpromazine, the antipsychotic, showed some antidepressant effect in a couple of studies.

It is.

And it just shows how messy and overlapping these drug effects can be.

But, and we have to keep coming back to this, these trials all suffered from the same old methodological problems.

The blind was broken by side effects.

Of course.

Transient sedation, dry mouth, all the usual suspects.

Plus, a lot of the studies that failed to show a difference were probably just poorly designed.

Too few patients, too low a dose, or they lumped in patients who were never going to respond anyway.

Which brings us to the really crucial question.

Who is the responder group?

Who are these drugs for?

This is where the work of a researcher named Kilo was so important.

He used a statistical method to look at patient symptoms and see which ones predicted a good response to imipramine.

And what did he find?

What kind of depression responds well to tricyclics?

He found that the best response was in patients with what's called endogenous or psychotic depression.

This is a type of depression that seems to come more from within, from a biological cause rather than as a direct reaction to life events.

What are the classic symptoms of that endogenous profile?

It's a sadness that feels qualitatively different from normal sadness.

You see deep feelings of guilt, of being worthless.

You see psychomotor changes, either being very slowed down or very agitated.

And two big physical signs are key.

Early morning waking and significant weight loss.

And who are the poor responders?

The patients who had more hysterical or hypochondriacal features, a lot of self -pity or long -standing neurotic problems.

That distinction is really held up over time.

Tricyclics are for that more biological endogenous pattern of depression.

Though the source does mention some other more surprising groups that can respond.

Yeah, some reports suggest they can help with obsessive compulsive disorder and even some bizarre pain syndromes, which points to a much broader role for mono means in the brain than just mood.

Okay, let's go back to the MAO inhibitors.

If we look at table 17 .2, which compares them directly to imipramine, what's the story there?

The story is that they are generally less effective.

In head -to -head trials, none of the MAOIs were found to be more effective than imipramine.

At best, a few studies found them to be equal.

So less effective.

And that's before we even get to the danger factor.

The danger factor is huge.

It's why they're not a first -line treatment.

Because they block that MAO enzyme, they allow certain compounds from food to build up in the body.

Specifically, presser amines.

And presser amines cause your blood pressure to spike.

Dramatically.

The MAO enzyme normally breaks these down in your gut, but with the enzyme blocked by the drug, these presser amines get into your bloodstream.

And they come from foods that are pretty common.

Very common.

Aged cheeses, red wines, certain beans, yeast extracts like marmite.

If a patient on an MAOI eats these foods, they could have a hypertensive crisis, a massive sudden spike in blood pressure that can cause a stroke and even death.

That's a terrifying risk.

And given their lower efficacy, you can see why they fell out of favor.

But there was one last attempt to find a niche for them.

Right.

A hypothesis from a researcher named Sargent.

He suggested that MAOIs were for atypical depressives.

The same group that didn't respond well to the tricyclics, the neurotic hypochondriacal patients.

Exactly.

The idea was that there were two different kinds of depression biochemically, and each drug class treated one type.

It was a neat idea, but unfortunately,

later trials didn't really support it.

Okay.

So let's now make a pretty big leap from brain chemistry to something much more direct.

Electroconvulsive therapy, or ECT.

This is one that produces maybe the most rapid response, but it's also probably the least understood.

Yeah.

And the history starts with a completely flawed idea.

The belief in the 1930s was that you couldn't have both epilepsy and schizophrenia at the same time.

So the idea was if you give a schizophrenic patient a seizure, it might help their schizophrenia.

That was the logic.

A doctor named Von Meduna started it in 1935, inducing convulsions with camphor and oil.

Then Sirletti and his team switched to using electric current a year later.

And they found it didn't really work that well for schizophrenia.

Not for the core symptoms, no.

But they saw these remarkable, dramatic, rapid improvements in patients with severe depression.

What always strikes me is the brute fact of it.

Neurologically, the effect is identical to a major epileptic seizure.

It is.

And the immediate psychological effect of that is a state of confusion, followed by amnesia for the event itself.

And over a course of treatments, that amnesia can extend to the whole treatment period.

And that memory loss is the source of so much public fear.

So you point to a much more interesting explanation called state -specific learning.

This is one of the most fascinating concepts in the whole chapter.

The idea is that the amnesia isn't because the memory traces are being erased.

It's that the memories formed during the recovery from ECT can only be recalled when you are back in that specific post -seizure state.

Wow.

So the memory is there, but it's locked away.

And the key to unlock it is another round of ECT.

It's like the retrieval cue is the neurological state itself.

And since a patient is only in that state for a short time after each treatment, they effectively lose access to the memories of the entire treatment period.

So during the course of treatment, memory is just generally impaired.

Very much so.

Short -term recall, long -term recall, even recall of events from before the treatment started can be affected.

And if you give ECT too often, like more than three times a week, patients can become grossly confused and disoriented.

Is there anything they do in modern practice to reduce that confusion?

Yes.

They found that if you deleter the electrical stimulus only to the patient's non -dominant cerebral hemisphere, for most right -handed people, that's the right side of the brain.

The confusion is significantly less.

Presumably because you're sparing the left hemisphere, which is so crucial for language and verbal memory.

That's the leading theory, yes.

Though it's possible you're just shifting the impairment to non -verbal memory, which is harder to test.

And what about after the treatment course is over?

Does the memory come back?

Memory for distant events, things from long before the treatment, that comes back completely.

But the amnesia for the treatment period itself and for the time immediately before it started, that often remains.

Now the big question.

Is there any link between all this memory disruption and how well the treatment works?

None whatsoever.

There is zero evidence that the amount of memory loss or how scared the patient is has anything to do with the therapeutic effect.

It's a side effect.

It is not the mechanism of action.

So we can completely dismiss that old snake pit idea that it just scares people into getting better.

So who does it help?

Who is the ECT responder group?

It's the exact same profile as the tricyclic antidepressants.

The endogenous or psychotic depressives are the ones who respond best.

But it's used for more than just depression.

Yes.

A certain group of schizophrenic patients respond well, particularly those with a lot of hallucinations and strong mood symptoms.

It's less useful for the flat affect type of schizophrenia.

And it's also extremely effective at controlling states of manic excitement.

So its clinical role seems to be for severe psychotic emotional states where you need a very rapid and powerful intervention.

That's it, exactly.

It's used when there's a real risk of death from suicide or just physical exhaustion.

And you don't have weeks to wait for a drug to kick in.

Okay, if the memory loss isn't the mechanism, what do we know about why it works?

What are the biochemical clues?

Well, we know that these severe mood disorders involve changes in brain chemicals, amines, and electrolytes.

And after ECT, we see those chemical levels start to return to normal.

So the brain chemistry is normalizing.

Yes.

But here's the catch.

We don't know if the ECT is causing those changes directly or if those changes are just a marker of the brain getting better through some other unknown mechanism that the seizure triggers.

The mystery remains.

From electricity, we now move to most invasive and historically controversial treatment of all, psychosurgery.

What's so incredible here is the journey this field has taken.

It went from these really crude, haphazard, destructive procedures to these unbelievably precise targeted interventions.

And like so many other things, the inspiration came from animal research.

It did.

The key finding was in 1935 from Fulton and Jacobson.

They removed the frontal lobes from chimpanzees and found that their frustration and aggression just vanished.

Fulton famously said the most ferocious messians were reduced to friendly docility.

And a physician named Muniz heard that and thought,

maybe this could help my human patients with their irrational fears and obsessions.

Exactly.

And his early reports were so enthusiastic that it just took off.

Over the next 15 years, something like 20 ,000 people had frontal lobotomies.

But the cost was just devastating.

Devastating.

The early techniques were so crude, they destroyed huge areas of the frontal lobe.

The result was that moderate to severe intellectual impairment, emotional blunting, major personality changes.

That wasn't a risk, that was the expected outcome.

And the field basically died out for a while, right?

Pushed aside by the new drugs and a more humanistic approach to psychiatry.

It almost vanished completely.

But interest came back because of two huge developments.

The first was a scientific one.

By studying the few patients who actually did well, they realized the benefit didn't come from destroying the whole frontal lobe.

It came from severing the very specific connections between the frontal lobe and the limbic system, the frontal limbic connections.

So they realized they didn't need a sledgehammer.

They needed a scalpel to cut one specific pathological circuit.

And the second development was the technology to do just that, stereotactic surgery.

This allows a surgeon to go into the brain with millimeter precision and create a tiny targeted lesion exactly where those connections are.

And this precision defines modern psychosurgery, which we can split into two types.

Let's start with type one, surgery for depression, anxiety, and obsession.

So these procedures target very specific areas, the lower medial quadrant of the frontal lobe, the cingulate gyrus.

The goal is to interrupt the pathways that let the cognitive parts of the brain, the parts that ruminate and worry, get stuck in a feedback loop with the emotional effect of parts of the brain.

You're cutting the connection between the obsessive thought and the overwhelming anxiety it produces.

That's the idea.

And it's important to note that ethically, the patients getting these operations today are usually perfectly capable of giving rational consent.

They're suffering from these awful treatment -resistant conditions, but their decision -making capacity is intact.

A great example of this is the procedure called limbic leukotomy.

This is a very precise surgery where tiny lesions are made in both the cingulate gyrus and the lower medial frontal lobe.

The typical patient has been suffering for a decade or more from an intractable condition that has failed every other treatment.

And what are the results like?

The results shown in our source material from a study of 29 patients are really striking.

Scores for obsession, anxiety, depression, all of it, were significantly down at a 17 -month follow -up.

And they continue to improve over time.

And crucially, without the horrific side effects of the old lobotomies.

Exactly.

No emotional blunting, no personality changes, no post -op epilepsy.

In fact, their intelligence scores often went up a little, probably because they were no longer crippled by their symptoms.

The sources also mention an even more tailored approach.

Yes, from the Burden Neurological Institute.

This is amazing.

They implant these hair -fine electrodes and leave them in for months.

And they test different spots by sending a small current to temporarily block the circuit.

So they can see in real time which connections are part of the problem.

And only the spots that produce symptom relief when they're blocked are then chosen for a permanent lesion.

It's truly personalized psychosurgery based on function, not just anatomy.

Now let's turn to the other type, type II, which is for controlling pathological aggression.

And this is where the ethics get much, much harder.

They do.

These operations, like an amygdala, were inspired by those animal studies that show taming effects when you damage the amygdala.

And the target patients here are?

Usually highly aggressive and emotionally disturbed children, often with epilepsy,

or in the past, prisoners.

And the operations did have a marked calming effect in most cases.

But they weren't a complete solution.

No, they didn't entirely get rid of the violent outbursts.

And when you weigh that partial benefit against the risks of brain surgery.

And the near impossibility of getting truly meaningful consent from a child or a prisoner.

It becomes ethically precarious.

These operations are not widely accepted and are viewed with extreme caution pretty much everywhere.

But even with the most modern, precise psychosurgery, we still have that same old problem.

How do you know it's really the surgery that's working?

It's so hard.

You have the massive placebo effect of just undergoing brain surgery.

You have the intensive rehab that comes after.

These are huge confounding factors.

And you can't have a true control group.

You can't do dummy operations, where you open the skull but don't make the lesion.

It's an ethical non -starter.

But you can make a reasonable inference.

Because these surgeries are only ever done as a last resort.

Right.

They're only for patients who have failed every single other therapy.

So in a way, each patient acts as their own control.

The fact that they finally respond to this, after nothing else worked, is strong, though not perfect, evidence that the procedure itself is effective.

Okay, let's wrap this up with our final treatment, which is a fascinating contrast to everything else.

Lithium.

It's incredibly specific for one illness, but its mechanism is a complete puzzle.

Lithium salts were discovered, again, accidentally, by an Austrian doctor named Cade in 1949.

He found they were a specific treatment for acute mania, the high phase of what we now call bipolar disorder.

But the real breakthrough was in 1968, when its use was expanded.

That's when a researcher named Shao showed that lithium wasn't just for treating an acute manic episode.

It was a prophylactic.

It could prevent relapses of both the mania and the depression in manic depressive illness.

That changed everything.

And what makes lithium so special from a research perspective?

It's the one drug that lets you do a clean, double -blind trial.

It is the exception that bears the rule.

Because when you give lithium at the correct therapeutic dose, which you monitor with blood tests, it produces no discernible side effects.

No dry mouth, no tremors, no sedation, nothing to break the blind.

Nothing.

So you can genuinely maintain the double -blind.

And when they did that, the evidence was just overwhelming.

It was just a big trial by Copen and others.

And the results were just night and day.

Completely.

Over two years, 86 % of the patients on lithium had little or no symptoms.

In the placebo group, it was only 8%.

That 86 % versus 8 % gap is just.

It's irrefutable proof of a specific therapeutic effect.

But even though it's clean at the right dose, it's very dangerous if you get the dose wrong.

Very dangerous.

An overdose causes drowsiness, loss of coordination, nausea, and can lead to coma and death.

Yeah.

That's why the regular blood monitoring is non -negotiable.

And here's the great irony.

We have this incredibly specific, undeniably effective drug, and we have no idea how it works.

We really don't.

We know it interferes with all sorts of things in the body, sodium, potassium, magnesium, metabolism.

We know it affects brain amines, like noradrenaline.

But how those broad chemical changes translate into the specific mood stabilization needed for bipolar disorder is a total mystery.

It just brings us right back to where we started.

We have these potent tools.

We can see the effect.

But the why is still lost in the mist.

So if we try to connect this all back to the big picture, what's the major takeaway from this whole field?

For me, it's that tension.

The tension between having these incredibly powerful techniques and the profound uncertainty about how and why they work.

We can produce these complex changes in the brain, but figuring out which of those changes is the one that's actually helping.

The light has only just started to get through the mist on that.

And for most of these treatments, we still don't have genuinely well -controlled trials because of that side effect problem that makes a true double -blind almost impossible.

Lithium is the great exception.

And then there's what the source calls academic chaos.

The constant flood of new drugs means clinicians are always chasing the next new thing instead of doing the really slow painstaking work to figure out which of our current treatments works best for which specific patient.

It's a sign of a healthy growing field, but it's a chaotic one.

It is.

The hope is that we're just now starting to do that serious, precise follow -up work.

But it's a long road.

That's a perfect place to land.

Let's do a quick recap of the most important ideas for everyone listening.

We started with the core problem,

trying to separate a treatment's real effect from spontaneous cure and the placebo effect made even harder by fuzzy diagnoses and the side effect issue.

We saw how the major tranquilizers, the phenothiazines, seem to work by turning down the volume on the outside world, helping to filter out distracting stimuli for psychotic patients.

We covered the antidepressants, both of which boost monoamines in the brain, but with a mysterious time lag.

And we saw they work best for that endogenous biological type of depression.

We talked about ECT, a rapid and powerful treatment for life -threatening mood states, whose therapeutic effect is separate from its strange state -specific effects on memory.

And we tracked psychosurgery's journey from the brutal lobotomy to today's precision stereotactic surgery, which targets specific frontal limbic circuits to help with intractable obsessions and anxiety.

And finally, we looked at lithium, the gold standard for bipolar disorder and the gold standard for psychiatric research, because its lack of side effects allowed for truly clean trials, even if its mechanism remains a puzzle.

So,

you know, when you step all the way back, it's amazing.

We've gone from a neolithic shaman drilling a hole in a skull to a surgeon using stereotactic robots.

But the fundamental struggle is exactly the same.

It's still about isolating that one genuine therapeutic needle from the giant messy haystack of hope, belief and the body's own capacity to heal.

The journey is far from over.

It certainly is.

Thank you for joining us for this really essential and, I think,

complex look into the physical treatments of psychology.

We hope this deep dive has given you a clearer, more critical way to think about this field.

Until next time.

We'll see you soon for the next deep dive.